This paper is only available as a PDF. To read, Please Download here.
Abstract
Between September 1, 1989 and October 31, 1994, 173 post-menopausal breast cancer
women on tamoxifen treatment were followed up in the authors' institutions. During
this period, 14 (8.1%) underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy
for various indications. Eight (57.1%) were found to have adenomyosis, of whom one
had a large fundal adenomyotic lump and the other seven patients had two to four small
microscopic fact of adenomyosis. In this study, the rate of adenomyosis described
among those postmenopausal breast cancer patients treated with tamoxifen is nearly
three to four times higher than the rate reported in the literature for pre- and postmenopausal
women. There is no previous reported increased incidence of adenomyosis in postmenopausal
breast cancer patients treated with tamoxifen. Thus, it is suggested that the prolonged
and unopposed estrogen-like stimulation by tamoxifen may play a causal role rather
than be a casual factor in the development of this pathologic entity.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 1995 Academic Press. Published by Elsevier Inc. All rights reserved.
